The TGF-β1 signalling pathway, has been proposed as a potential therapeutic target to treat the Neuro-PASC symptoms in the chronic phase based on its immune suppressing effect (Oronsky et al., 2023). The gene discussed is TGFB1; the disease is long COVID-19.